User: I want to know more about the compound with SMILES CC[C@H]1C2=CC3=NC(=C(CC(=O)OC)C4=NC(=CC5=C(C)/C(=C(\C)[O-])C(=N5)C=C(N2)[C@@H]1C)[C@@H](C)[C@@H]4CCC(=O)O)C(C([O-])=NCCS(=O)(=O)O)=C3C.[Pd+2].
Assistant: That sounds interesting, how can I help?
User: Please describe this drug.
Assistant: The answer is Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a focal treatment for localized prostate cancer. It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland. Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.
User: I want to know more about the {#molecule|chemical|compound!} with {SMILES__description} {SMILES#}.
Assistant: {#Sure, what is your question?|How can I help?|That sounds interesting, how can I help?|Interesting, how can I help?!}
User: {quest#}
Assistant: {#The answer is |!}{answ#}
CC[C@H]1C2=CC3=NC(=C(CC(=O)OC)C4=NC(=CC5=C(C)/C(=C(\C)[O-])C(=N5)C=C(N2)[C@@H]1C)[C@@H](C)[C@@H]4CCC(=O)O)C(C([O-])=NCCS(=O)(=O)O)=C3C.[Pd+2]
CC[C@@H]1[C@H](C2=CC\3=NC(=C(/C3=C(\C)/[O-])C)C=C4[C@H]([C@@H](C(=N4)C(=C5C(=C(C(=N5)C=C1N2)C)C(=NCCS(=O)(=O)O)[O-])CC(=O)OC)CCC(=O)O)C)C.[Pd+2]
(7R,8R,12Z,17S,18S)-18-(2-carboxyethyl)-7-ethyl-20-(2-methoxy-2-oxoethyl)-3,8,13,17-tetramethyl-12-(1-oxidoethylidene)-N-(2-sulfoethyl)-8,17,18,22-tetrahydro-7H-porphyrin-2-carboximidate;palladium(2+)
Please describe this drug.
Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a focal treatment for localized prostate cancer. It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland. Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.